Exhibit 10.1
SEPARATION AGREEMENT
This Separation Agreement (the “Agreement”) by and between Jamie Dananberg, M.D. (“Executive”), and Unity Biotechnology, Inc., a Delaware corporation (the “Company”), is made effective as of the eighth (8th) day following the date Executive signs this Agreement (the “Effective Date”) with reference to the following facts:
A. Executive’s employment with the Company and each of its affiliates ended on April 30, 2023 (the “Termination Date”).
B. Executive and the Company want to end their relationship amicably and also to establish the obligations of the parties including, without limitation, all amounts due and owing to Executive.
NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, the parties agree as follows:
1
|US-DOCS\140495091.4||
2
|US-DOCS\140495091.4||
3
|US-DOCS\140495091.4||
4
|US-DOCS\140495091.4||
“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.”
5
|US-DOCS\140495091.4||
BEING AWARE OF SAID CODE SECTION, EXECUTIVE HEREBY EXPRESSLY WAIVES ANY RIGHTS EXECUTIVE MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT.
6
|US-DOCS\140495091.4||
7
|US-DOCS\140495091.4||
(Signature page(s) follow)
8
|US-DOCS\140495091.4||
IN WITNESS WHEREOF, the undersigned have caused this Separation Agreement to be duly executed and delivered as of the date indicated next to their respective signatures below.
DATED: April 27, 2023 | By: | /s/ Jamie Dananberg | |
Name: | Jamie Dananberg | ||
| |||
|
|
| UNITY BIOTECHNOLOGY, INC. |
|
|
|
|
DATED: April 27, 2023 |
| By: | /s/ Anirvan Ghosh |
|
| Name: | Anirvan Ghosh |
|
| Title: | CEO |
A-1
|US-DOCS\140495091.4||